

# ENOCHIAN BIOSCIENCES IS A HOUSE OF CARDS – THE PIPELINE IS ENTIRELY PRE-CLINICAL AND MANAGEMENT HAS A QUESTIONABLE HISTORY

November 19, 2019



## RESEARCH SUMMARY

---

Enochian Biosciences (ENOB) is a pre-clinical stage biotech which purchased its HIV drug patents from Weird Science, LLC.

ENOB's lead scientist and HIV patent inventor does not appear to have any biotech experience, was accused of identity theft, and plead guilty to commercial burglary in 2018.

ENOB's lead scientist appears to have had a romantic relationship with the partner of Weird Science, which further puts the patents' validity into question.

ENOB is already behind schedule with its pre-clinical targets.

With no data and a questionable history, we conclude that ENOB should be valued at \$10M, or \$0.25 a share, at best.

---

Enochian Biosciences (ENOB) is a pre-clinical stage biotech which purchased its HIV drug patents from Weird

Science, LLC.

ENOB's lead scientist and HIV patent inventor does not appear to have any biotech experience, was accused of identity theft, and plead guilty to commercial burglary in 2018.

ENOB's lead scientist appears to have had another association with the partner of Weird Science, which further puts the patents' validity into question.

ENOB is already behind schedule with its pre-clinical targets.

With no data and a questionable history, we conclude that ENOB should be valued at \$10M, or \$0.25 a share, at best.

Read the full report on Seeking Alpha [here](#).



Independent institutional-grade research focused on identifying asymmetric risks in small and micro-cap equities.

---

## LEGAL DISCLAIMER

As of the publication date of our reports, White Diamond Research, along with its clients, affiliates, and related entities, may have a short position in the securities discussed and stand to realize significant gains in the event that the price of the stock declines. Use White Diamond Research at your own risk. You should do your own research and due diligence before making any investment decision. No information contained in our reports should be interpreted as financial advice.

© 2026 White Diamond Research LLC